KathleenLomaxMD

PubMed

• 7 citations
  Impact of systemic juvenile idiopathic arthritis/Still's disease on adolescents as evidenced through social media posts.
  Renee F. Modica, Kathleen G Lomax, Pamela Batzel, Armelle Cassanas
  Open Access Rheumatology. 2018-06-13

Journal Articles

• Impact of Systemic Juvenile Idiopathic arthritis/Still’s Disease on Adolescents as Evidenced Through Social Media Posts  
  Renee F Modica, Kathleen G Lomax, Open Access Rheumatology: Research and Reviews
• The family journey to diagnosis with systemic juvenile idiopathic arthritis: a cross-sectional study of the changing social media presence  
  Modica, R.F., Lomax, K.G., Batzel, P., Shapardanis, L., Katzer, K.C., Elder, M.E., Open Access Rheumatology: Research and Reviews, 1/1/2016
• Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis: comment on the ...  
  Brunner, H., Lomax, K.G., Levy, S., Arthritis & Rheumatology, 1/1/2015
• Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data ...  
  Salvatori, R. Woodmansee, W.W., Molitch, M., Gordon, M., Lomax, K.G., Pituitary, 1/1/2014
• Patient perspectives on the impact of acromegaly: Results from individual and group interviews  
  Gurel, M.H., Bruening, P.R., Rhodes, C., Lomax, K.G., Patient Preference and Adherence, 1/1/2014
• Managing the Child with Severe Primary Insulin-like Growth Factor-1 Deficiency (IGFD): IGFD Diagnosis and Management  
  Cohen, J., Blethen, S., Kuntze, J., Smith, S.L., Lomax, K.G., Mathew, P.M., Drugs in R&D, 1/1/2014
• Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease  
  Schreiber, S., Reinisch, W., Colombel, J-F, Sandborn, W.J., Hommes, D.W., Robinson, A.M., Huang, B., Lomax, K.G., Pollack, P.F., Journal of Crohn's and Colitis, 1/1/2013
• Serum adalimumab concentration and clinical remission in patients with Crohn’s disease  
  Chu, Y.-L., Rubin, D.T., Vermeire, S., Louis, E., Robinson, A.M., Lomax, K.G., Pollack, P.F., Paulson, S.K., Inflammatory Bowel Diseases, 1/1/2013
• Patient perspectives on the impact of Crohn's disease: results from group interviews  
  Norton, B-A., Thomas, R., Lomax, K.G, Dudley-Brown, S., Patient Preference and Adherence, 1/1/2012
• Adalimumab for the Induction and Maintenance of Clinical Remission in Japanese Patients With Crohn's Disease  
  Watanabe, M., Hibi, T., Lomax, K.G., Paulson, S. K., Chao, J., Alam, M.S., Camez, A., Journal of Crohn’s Colitis, 1/1/2012
• Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial  
  Rutgeerts, P., Van Assche, G., Sandborn, W.J., Wolf, D.C., Geboes, K., Colombel, J.F., Reinisch, W., Kumar, A., Lazar, A., Camez, A., Lomax, K.G., Pollack, P.F., D'Hae..., Gastroenterology, 1/1/2012
• The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life, and increased work productivity in patients with Crohn's disease who faile...  
  Lichtiger, S., Binion, D.G., Wolf, D.C., Present, D.H., Bensimon, A.G., Wu, E., Yu, A., Cardoso, A.T., Chao, J., Mulani, P.M., Lomax, K.G., Kent, J.D., Alimentary Pharmacology & Therapeutics, 1/1/2010
• Adalimumab for the treatment of fistulas in patients with Crohn's disease  
  Colombel, J.F., Schwartz, D.A., Sandborn, W.J., Kamm, M.A., D’Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., Kent, J.D., Lomax, K.G., Poll..., Gut, 1/1/2009
• Comparison of two adalimumab treatment schedule strategies for moderate to severe Crohn’s Disease: Results from the CHARM study  
  Colombel J.F., Sandborn, W.J., Rutgeerts, P., Kamm, M., Yu, A.P., Wu, E.Q., Pollack, P.F., Lomax, K.G., Chao, J.D., Mulani. P., Am J Gastroenterol, 1/1/2009
• Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results from the CHARM Study  
  Feagan, B.G., Panaccione, R., Sandborn, W.J., D’Haens, G.R., Schreiber, S., Rutgeerts, P.J., Loftus, E.V., Lomax, K.G., Yu, A.P., Qu, E.Q., Mulani, P., Gastroenterology, 1/1/2008
• Pharmacokinetics and Tolerability of Rabeprazole Sodium in Subjects Aged 12 to 16 Years with Gastroesophageal Reflux Disease: An Open-Label, Single- and Multiple-Dose ...  
  James, L., Walson, P., Lomax, K., Kao, R., Varughese, S., Reyes, J. et al, Clinical Therapeutics, 1/1/2007
• Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn  
  Warrington, S., Baisley, K., Lee, D., Lomax, K., Delemos, B., Boyce, M., Morocutti, A., Aliment Pharmacol Ther, 1/1/2007
• Yellow mice, red hair, and childhood obesity: the melanocortinergic pathway in energy homeostasis  
  Graham, K.S., Leibel, R.L., J Pediatrics, 1/1/2001
• Olanzapine toxicity in a toddler  
  Yip, L., Dart, R.C., Graham, K., Pediatrics, 1/1/1998
• ERCP in the management of pediatric pancreatitis  
  Graham, K.S., Ingram, D.J., Steinberg, S.E., Narkewicz, M.R., Gastrointestinal Endoscopy, 1/1/1998
• Resolution of cavopulmonary shunt associated arteriovenous malformation after heart transplantation  
  Graham, K., Sondheimer, H., Schaffer, M., Journal of Heart and Lung Transplantation, 1/1/1997
• Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test  
  Klein, P.D., Malaty, H.M., Martin, R.F., Graham, K.S., Genta, R.M., Graham, D.Y., American Journal of Gastroenterology, 1/1/1996
• Variability with omeprazole amoxicillin combinations for treatment of Helicobacter pylori infection  
  Graham, K.S., Malaty, H., El-Zimaity, H.M.T., Genta, R., Cole, R., Al-Assi, M., Yousfi, M., Neil, G.A., Graham, D.Y., American Journal of Gastroenterology, 1/1/1995
• Accumulation of the insoluble PiZ variant of the human alpha-one-antitrypsin within hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP  
  Graham, K.S., Le, A., Sifers, R.N., Journal of Biological Chemistry, 1/1/1990
• Intracellular degradation of the transport-impaired human PiZ alpha-one-antitrypsin variant  
  Le, A., Graham, K.S., Sifers, R.N., Journal of Biological Chemistry, 1/1/1990
• Join now to see all

Books/Book Chapters

• The 5 Minute Pediatric Consult. 
  Chapter: Gastritis 
  Page 386 - 387Lomax, K.G.Editors: Schwartz, M. W..Lippincott Williams and Wilkins, Philadelphia, PAEdition 2nd,2005
• The 5 Minute Pediatric Consult. 
  Chapter: Volvulus 
  Page 898 - 899Lomax, K.G.Editors: Schwartz, M. W..Lippincott Williams and Wilkins, Philadelphia, PAEdition 2nd,2005
• Contemporary Diagnosis and Management of H. pylori-Associated GI Diseases 
  K.G. Lomax and D.Y. GrahamEdition 3rd,2005
• Contemporary Diagnosis and Management of H. pylori-Associated GI Diseases 
  K.G. Lomax and D.Y. GrahamEdition 2nd,2002
• The 5 Minute Toxicology Consult. 
  Chapter: Bismuth 
  Page 264 - 265Graham, KEditors: Dart, R..Lippincott Williams and Wilkins, Philadelphia, PA2000
• The 5 Minute Toxicology Consult. 
  Chapter: Cisapride 
  Page 324 - 325Graham, KEditors: Dart, R..Lippincott Williams and Wilkins, Philadelphia, PA2000
• The 5 Minute Toxicology Consult. 
  Chapter: Pennyroyal 
  Page 560 - 561Graham, KEditors: Dart, R..Lippincott Williams and Wilkins, Philadelphia, PA2000
• The 5 Minute Pediatric Consult. 
  Chapter: Obesity 
  Page 580 - 581Graham, KEditors: Schwartz, M. W..Lippincott Williams and Wilkins, Philadelphia, PA2000
• Contemporary Diagnosis and Management of H. pylori-Associated GI Diseases 
  K.G. Lomax and D.Y. GrahamEdition 1st,1998
• Join now to see all

Abstracts/Posters

• Impact of Systemic Juvenile Idiopathic Arthritis/Still's Disease on adolescents as evidenced through social media posting.
  Modica, R.F, Lomax, K.G., Batzel, P., Cassanas, A., Elder, M.E., PRES Meeting; EULAR Annual Scientific Meeting, 1/1/2016
• Impact of Familial Mediterranean Fever, MKD/HIDS, and TRAPS on patients and families, data from patient interviews.
  Hausmann, J.S., Lomax, K.G., Shapiro, A., Durrant, K.L., PRES Meeting; EULAR Annual Scientific Meeting, 1/1/2016
• The disease burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international health related quality of life survey and retrospective char...
  Shenoi, S., Horneff, G., Cidon, M., Ramanan, A., Kimura, Y., Quartier, P., Foeldvari, I., Zeft, A., Lomax, K.G., Gregson, J., Campbell, S., Weiss, J., Marinsek, N., Pa..., ACR Meeting, 1/1/2016
• The patient experience of colchicine resistant Familial Mediterranean Fever (cr-FMF): Patients' views on their disease journey.
  Durrant, K., Lomax, K.G., Gregson, J., HTAi Annual Meeting; RWCS, 1/1/2016
• Hyper immunoglobulin D syndrome (HIDS): Patient’s views of their disease journey.
  Durrant, K., Lomax, K.G., Gregson, J., HTAi Annual Meeting; RWCS, 1/1/2016
• Living with Tumor Necrosis Factor Receptor-Associated periodic fever (TRAPS): Patient's views of their disease journey.
  Durrant, K., Lomax, K.G., Gregson, J., RWCS, 1/1/2016
• The family journey to diagnosis with systemic juvenile idiopathic arthritis as evidenced through changing social media presence.
  Modica, R.F., Lomax, K.G., Batzel, P., Shapardanis, L., Compton, K.A., Elder, M.E., ACR, 1/1/2015
• Screening for comorbid conditions in patients enrolled in the SODA Acromegaly Registry.
  Woodmansee, W., Salvatori, R., Lomax, K.G., ENDO, 1/1/2014
• Compliance and Persistence to Somatostatin Analog Therapy for the Treatment of Acromegaly.
  Gurel, M.H., Han, Y., Furtado, A., Lomax, K.G., ENDO, 1/1/2014
• Efficacy of recombinant human IGF-1 (rhIGF-1) in patients with severe primary IGF-1 deficiency (IGFD): nearly two decades of follow-up from the pivotal trial.
  Backeljauw, P.F., Calikoglu, A.S., Duncan, V.G., Blethen, S., Kuntze, J., Frane, J., Lomax, K.G., Chernausek, S.D., ENDO, 1/1/2014
• PYRAMID Registry: An Observational Study of Adalimumab in Crohn’s Disease at Year 3.
  D’Haen’s, G.D., Reinisch, W., Satsangi, J., Loftus, E.V., Panaccione, R., Tokimoto, D., Wang, Y., Lomax, K.G., ACG; UEGW, 1/1/2011
• Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis: data from controlled trials.
  Feagan, B.G., Sandborn, W.J., Yang, M., Lomax, K.G., Lazar, A., Thakkar, R.T., Mulani, P., Chao, J., ACG; UEGW, 1/1/2011
• Patient perspective on impact of Crohn's Disease (CD): Results from Group Interviews.
  Lomax, K.G., SGNA; NASPGHAN, 1/1/2010
• Evaluation of Potential Correlations between Serum Adalimumab Concentration and Remission in Patients with Crohn’s Disease in CLASSIC I and II.
  Li, J., Robinson, A.M., Lomax, K.G., Pollack, P.F., Paulson, S. K., ECCO; DDW, 1/1/2010
• Achievement of Early Deep Remission Predicts Better Long-Term Outcomes For Adalimumab-Treated Patients With Crohn's Disease: Data From EXTEND.
  Sandborn, W.J., Colombel, J.F., Rutgeerts, P., M., Lomax, K.G., Pollack, P.F., Thakkar, R.B., Camez, A., Chen, N., Chao, J.D., Mulani, P.M., ACG; UEGW, 1/1/2010
• Effect of disease duration on “deep remission:” results from the EXTEND trial.
  Colombel, J.F., Schreiber, S., Rutgeerts, P., Sandborn, W.J., Yang, M., Lomax, K.G., Pollack, P.F., Thakkar, R.B., Camez, A., Huang, B., Zhou, Q., Mulani, P.M., Chao, ..., ACG; UEGW, 1/1/2010
• Achievement of Early Deep Remission Is Associated With Lower Rates of Weekly Dosing for Adalimumab-Treated Patients With Crohn’s Disease: Data From EXTEND.
  Sandborn, W.J., Colombel, J.F., Lomax, K.G., Pollack, P.F., Thakkar, R.B., Camez, A., Chen, N., Yang, M., Chao, J.D., Mulani, P.M., ACG, 1/1/2010
• Patient reported outcomes with adalimumab for patients previously treated with high-dose infliximab for Crohn’s disease.
  Panaccione, R., Louis, E., Binion, D.G., Yang, M., Chen, N., Lomax, K.G., Chao, J., Mulani, P.M., ACG, 1/1/2010
• PYRAMID Registry: Observational Study of Adalimumab in Crohn's Disease at Year 2.
  D’Haen’s, G.D., Reinisch, W., Satsangi, J., Loftus, E.V., Panaccione, R., Tokimoto, D., McNamee, L.P., Lomax, K.G., ACG, 1/1/2010
• Adalimumab maintains long-term remission in patients with moderately ro severely active Crohn’s disease through 3 years of therapy.
  Panaccione, R., Colombel, J., Sandborn, W.J., Rutgeerts, P., D’Haen’s, G.R., Lomax, K.G., Li, J., Pollack, P.F., ECCO; DDW, 1/1/2009
• Steroid-free remission in patients with Crohn's disease who received adalimumab therapy for at least 3 years: long-term results from CHARM.
  Kamm, M.A., Hanauer, S.B., Panaccione, R., Colombel, J., Sandborn, W.J., Lomax, K.G., Pollack, P.F., ECCO; DDW, 1/1/2009
• Outcome of patients with Crohn’s disease and primary sclerosing cholangitis in CHARM and GAIN.
  Panaccione, R., Rutgeerts, P., Wolf, D., Selby, W., Russel, M., Lomax, K.G., Pollack, P.F., ECCO, 1/1/2009
• Sustained Remission With Adalimumab Therapy in Japanese Patients With Moderately to Severely Active Crohn’s Disease.
  Hibi, T., Watanabe, M., Kumar, A., Camez, A., Lomax, K.G., ACG, 1/1/2009
• Adalimumab Downregulates Markers of Inflammation in Patients With Moderate to Severe Ileocolonic Crohn’s Disease: The Histologic Substudy of EXTEND.
  Geboes, K., Rutgeerts, P., Camez, A., Lazar, A., Lomax, K.G., ACG, 1/1/2009
• Adalimumab Maintains Long-Term Remission in Crohn’s Disease Through 2 Years.
  Panaccione, R., Colombel, J.F., Sandborn, W.J., Rutgeerts, P., D'Haens, G.R., Lomax, K.G., Li, J., Wong, R., Pollack, P.F., European Crohn's & Colitis Organization; DDW, 1/1/2008
• Join now to see all

Lectures

• Patient Perspectives on the Impact of Acromegaly: Results from Individual and Group Interviews. 
  1/1/2013
• The utility of ultrasound site selection for pediatric percutaneous liver biopsy. 
  1/1/1999